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Purpose: To determine whether regions of low apparent diffusion 
coefficient (ADC) with high relative cerebral blood volume 
(rCBV) represented elevated choline (Cho)-to–N-acety-
laspartate (NAA) ratio (hereafter, Cho/NAA ratio) and 
whether their volumes correlated with progression-free 
survival (PFS) and overall survival (OS) in patients with 
glioblastoma (GBM).
Materials and 
Methods:
This retrospective analysis was approved by the local re-
search ethics committee. Volumetric analysis of imaging 
data from 43 patients with histologically confirmed GBM was 
performed. Patients underwent preoperative 3-T magnetic 
resonance imaging with conventional, diffusion-weighted, 
perfusion-weighted, and spectroscopic sequences. Patients 
underwent subsequent surgery with adjuvant chemother-
apy and radiation therapy. Overlapping low-ADC and high-
rCBV regions of interest (ROIs) (hereafter, ADC-rCBV 
ROIs) were generated in contrast-enhancing and nonen-
hancing regions. Cho/NAA ratio in ADC-rCBV ROIs was 
compared with that in control regions by using analysis of 
variance. All resulting ROI volumes were correlated with 
patient survival by using multivariate Cox regression.
Results: ADC-rCBV ROIs within contrast-enhancing and nonen-
hancing regions showed elevated Cho/NAA ratios, which 
were significantly higher than those in other abnormal tu-
mor regions (P , .001 and P = .008 for contrast-enhancing 
and nonenhancing regions, respectively) and in normal- 
appearing white matter (P , .001 for both contrast-en-
hancing and nonenhancing regions). After Cox regression 
analysis controlling for age, tumor size, resection extent, O-
6-methylguanine-DNA methyltransferase-methylation, and 
isocitrate dehydrogenase mutation status, the proportional 
volume of ADC-rCBV ROIs in nonenhancing regions signif-
icantly contributed to multivariate models of OS (hazard 
ratio, 1.132; P = .026) and PFS (hazard ratio, 1.454; P = 
.017).
Conclusion: Volumetric analysis of ADC-rCBV ROIs in nonenhancing 
regions of GBM can be used to identify patients with poor 
survival trends after accounting for known confounders of 
GBM patient outcome.
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G lioblastoma (GBM) is the most ag-gressive malignant primary brain tumor in adults, with its charac-
teristic spatial and temporal intratu-
mor heterogeneity (1) being at least 
partly responsible for dismal patient 
outcome. Current surgical treatment of 
GBM aims to remove the contrast ma-
terial–enhanced component. Surround-
ing nonenhancing components, defined 
by T2-weighted signal hyperintensity, 
are largely left behind even though they 
harbor malignant tumor cells (2). This 
is done to avoid neurologic injury. De-
spite high-dose volume treatment, ad-
juvant radiation therapy applied to the 
nonenhancing component often fails 
to fully eliminate malignant cells, lead-
ing to local recurrence (3,4). Precise 
of survival were included in multivar-
iate regression models. In addition to 
age, these include extent of resection 
(30), enhancing tumor volume (31), O-
6-methylguanine-DNA methyltransfer-
ase (MGMT)-methylation status (32), 
and isocitrate dehydrogenase-1 (IDH-1) 
mutation status (33).
Our hypothesis was that ROIs of low 
ADC (implying high cellularity) with in-
tersecting high rCBV (implying vascular-
ity) would metabolically represent regions 
of tumor presence, as determined with 
the Cho/NAA ratio. The overall purpose 
was to determine whether regions of low 
ADC with high rCBV indicated an ele-
vated Cho/NAA ratio and whether their 
volumes correlated with progression-free 
survival (PFS) and overall survival (OS) 
in patients with GBM.
Materials and Methods
Patients
This study was approved by the local re-
search ethics committee, and signed in-
formed consent was obtained from each 
imaging details that underlie the non-
enhancing component remain unclear 
and relatively unexplored.
Various imaging methods have been 
assessed to probe biologic properties 
underlying GBM; these include the 
use of relative cerebral blood volume 
(rCBV) (5–8), apparent diffusion coef-
ficient (ADC) (7,9–14), or a combina-
tion thereof (7,15–17) to characterize 
tumor extent, guide resection, or yield 
prognostic information (18,19). ADC 
negatively correlates with cellularity 
in gliomas (10,13,20), and rCBV posi-
tively correlates with tumor vascularity 
(5) and cellular proliferation (21). With 
proton magnetic resonance (MR) spec-
troscopy (1H), metabolic ratios of cho-
line-containing compounds (Cho) to N-
acetylaspartate (NAA) (hereafter, Cho/
NAA ratio) correlate with tumor cellu-
larity, proliferation (22,23), and infiltra-
tion (24), making the Cho/NAA ratio a 
reliable measure with which to analyze 
differences or similarities in tumor pres-
ence among regions of interest (ROIs).
Studies that focus on the nonen-
hancing component are limited (25–
28). Volumetric properties of tissue 
with abnormal ADC and rCBV have not 
been extensively assessed in patients 
with GBM (29). In instances in which 
ADC and rCBV have been assessed 
(16), not all major confounding factors 
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Advances in Knowledge
 n Combining regions of low ap-
parent diffusion coefficient 
(ADC) with intersecting regions 
of high relative cerebral blood 
volume (rCBV) in patients with 
glioblastoma (GBM) generates 
spatially distinct regions of in-
terest (ROIs) that demonstrate a 
significantly elevated choline-to–
N-acetylaspartate ratio in com-
parison with that in other 
regions of the tumor (P = .008) 
and in contralateral normal-
appearing white matter (P , 
.001).
 n The increased proportion of 
these ROIs within the nonen-
hancing component of GBM 
carries prognostic information 
and is associated with poor over-
all survival (OS) (log-rank P = 
.017).
 n After accounting for age, tumor 
volume, extent of resection, 
O-6-methylguanine-DNA methyl-
transferase-methylation status, 
and isocitrate dehydrogenase-1 
mutation status, the proportion 
of these ROIs within nonenhanc-
ing regions significantly contrib-
utes to the model of OS (hazard 
ratio, 1.132; P = .026) and pro-
gression-free survival (hazard 
ratio, 1.454; P = .017).
Implications for Patient Care
 n Volumetric analysis of ADC and 
rCBV, especially within the non-
enhancing component, could 
yield valuable patient-specific in-
formation about potential sites 
that are responsible for failure of 
chemotherapy and radiation 
therapy.
 n Shifting focus from imaging fea-
tures of the contrast-enhancing 
component to those of the non-
enhancing component during in-
dividualized GBM assessment 
may result in the identification of 
regions that cannot be visualized 
with conventional MR imaging 
and that would be suited for tar-
geted boost radiation therapy or 
extended surgical resection.
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flip angle, 90°; field of view, 192 3 192 
mm; 19 sections; section gap, 1.5 mm; 
voxel size, 2.0 3 2.0 3 5.0 mm; acqui-
sition time, 141 seconds) with 9 mL of 
gadobutrol (1.0 mmol/mL, Gadovist; 
Bayer Schering Pharma, Berlin, Germa-
ny) followed by a 20-mL saline flush ad-
ministered via a power injector at a rate 
of 5 mL/sec, (e) a three-dimensional T1-
weighted sequence with gadolinuim che-
late injection (Gadovist; Bayer Schering 
Pharma) (900/2.98/900; flip angle, 9°; 
field of view, 256 3 240 mm; 176–208 
sections; no section gap; voxel size, 1.0 
3 1.0 3 1.0 mm; acquisition times, 252 
and 554 seconds), and (f) multivoxel two-
dimensional 1H MR spectroscopy chem-
ical-shift imaging with a semilocalized 
by adiabatic selective refocusing pulse 
sequence (2000/30–35; flip angle, 90°; 
field of view, 160 3 160 mm; voxel size, 
sections; 0.5-mm section gap; voxel size, 
0.7 3 0.7 3 5.0 mm; acquisition time, 
93 seconds), (b) a T2-weighted fluid-
attenuated inversion recovery sequence 
(repetition time msec/echo time msec/in-
version time msec, 7840–8420/95/2500; 
refocusing pulse flip angle, 150°; field of 
view, 250 3 200 mm; 27 sections; 1-mm 
section gap; voxel size, 0.8 3 0.8 3 4.0 
mm; acquisition time, 268 seconds), (c) 
diffusion-tensor imaging with a single-
shot echo-planar sequence (8300/98; flip 
angle, 90°; field of view, 192 3 192 mm; 
63 sections; no section gap; voxel size, 
2.0 3 2.0 3 2.0 mm; acquisition time, 
566 seconds) and with inline ADC cal-
culation using b values of 0–1000 sec/
mm2 to generate ADC parameters that 
reflect general clinical practice, (d) a 
postcontrast dynamic susceptibility con-
trast enhancement sequence (1500/30; 
patient. Preoperative data from 47 pa-
tients (mean age, 58.6 years; age range, 
28–75 years; 36 [76%] male patients) 
with subsequent histologic confirmation 
of GBM were prospectively collected 
(July 2010 to January 2012), and this was 
a retrospective analysis that included out-
come data. Exclusion criteria were pre-
vious cranial surgery, cerebral radiation 
therapy, or another known primary brain 
tumor. A total of 53 patients underwent 
baseline imaging (Fig 1). Three (6%) 
patients withdrew from the study after 
baseline MR imaging, and three (6%) 
had grade III astrocytomas. Resection 
was performed, on average, within 1 day 
of imaging (range, 0–9 days). All patients 
were taking a stable dose (8 mg/d) of 
dexamethasone. Surgery was performed 
with 5-aminolevulinic acid fluorescence, 
with the aim of completely resecting the 
contrast-enhancing area. Thereafter, pa-
tients underwent radiation therapy with 
concomitant and adjuvant chemotherapy. 
The extent of resection was assessed as 
a binary outcome of complete or partial 
resection of the contrast-enhancing re-
gion on the basis of findings of an early 
(,72 hours) postoperative MR imaging 
study. Patients were observed, and the 
response assessment in neuro-oncology 
criteria was used to identify progression, 
with postsurgical imaging findings as the 
baseline (34). Outcome measures were 
determined retrospectively. The dates of 
progression and death were recorded to 
calculate PFS and OS (ie, the number of 
days after surgery), respectively. Thirty 
(64%) of 47 patients were previously in-
cluded in a report on perfusion and dif-
fusion tensor imaging of GBM (35). This 
article reports the results of volumetric 
analysis of intersecting threshold-defined 
ADC and rCBV while using the Cho/NAA 
ratio to compare imaging profiles of tu-
mor presence.
MR Image Acquisition
Imaging was performed with a 3-T Mag-
netom Trio unit (Siemens Healthcare, 
Erlangen, Germany). Imaging sequences 
included (a) a previously described (35) 
axial T2-weighted sequence (repeti-
tion time msec/echo time msec, 4840–
5470/114; refocusing pulse flip angle, 
150°; field of view, 220 3 165 mm; 23–26 
Figure 1
Figure 1: Flowchart shows how patients were excluded. Six patients 
were excluded because of criteria set a priori. The remaining patients 
were excluded because of criteria set retrospectively. These included 
an ADC-rCBV ROI with a volume smaller than 50% of the chemical shift 
imaging voxel (2 cm3), an ADC-rCBV ROI located outside the chemical 
shift imaging grid, and a Cramer-Rao lower bound greater than 20%. 
All qualifying chemical shift imaging voxel values were recorded for 
ADC-rCBV ROIs; this resulted in 41 voxels from 20 patients in contrast-
enhancing regions and 43 voxels from 23 patients in nonenhancing 
regions.
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voxel, the 75th or 65th percentile of 
pooled rCBV voxels, would be used. 
Previously, ADC percentile values have 
ranged from 10% to 25% for analysis of 
heterogeneity (38) or texture (39) and 
survival (14). Thus, prior to inspection of 
data, the low ADC threshold was taken 
at the 15th percentile of the pooled vox-
els. Overlapping low ADC and high rCBV 
voxels were defined as ADC-rCBV ROIs. 
Because this method of threshold selec-
tion is specific, it must be determined 
whether overall conclusions of this study 
exclusively depended on the method of 
threshold establishment. To address this, 
test ROIs were generated by using per-
centile values for each individual patient. 
Thus, two sets of ADC-rCBV ROIs were 
compared with those in control subjects. 
These were main ROIs, which were gen-
erated with thresholds that were extract-
ed on a pooled-value basis by using data 
from all patients, as described previously, 
and test ROIs, which were generated 
with thresholds that were extracted on 
an individual basis, per patient. Test ROI 
volumes were generated to be compared 
with main ROI volumes and to undergo 
the same statistical analyses of survival. 
When referring to ADC-rCBV ROIs 
throughout this article, we refer to the 
main ROIs.
The contrast-enhancing regions were 
segmented by using semiautomated soft-
ware (GeoS; Microsoft Research, Cam-
bridge, England). Unenhanced regions 
were manually segmented with ImageJ 
software (National Institutes of Health, 
Bethesda, Md). A neuroradiologist with 
more than 4 years of experience (T.M.) 
segmented the test regions for interrater 
reliability testing. The Dice similarity coef-
ficient score was applied to presence and 
absence data and was used to compare 
the new test ROI mask data against the 
original reference mask, which was seg-
mented by the initial reader (N.R.B., .3 
years of brain tumor image analysis expe-
rience). The superimposed 1H MR spec-
troscopy data were analyzed as described 
previously (35). Only chemical shift im-
aging voxels in which the ROIs continued 
down the z-axis were included (Fig 2). 
The z-axis data were incorporated to 
further ensure that metabolite values re-
corded for the ADC-rCBV ROIs were due 
of rCBV were generated after contrast 
agent leakage correction, and they were 
based on the Boxerman (37) description. 
A standard population-based arterial in-
put function was automatically defined in 
the NordicICE (NordicNeuroLab) soft-
ware, and it was applied in a global man-
ner. As ADC values are dependent on the 
b value, ADC images were normalized to 
the contralateral normal-appearing white 
matter mean.
ADC and rCBV voxel data were 
pooled, and thresholds were established 
by using the histogram percentile values 
with Matlab software (MathWorks, 
Natick, Mass). Previously, high rCBV 
percentile values have ranged from 75% 
to 90% for image-guided biopsy studies 
of glioma heterogeneity (21). Thus, the 
rCBV threshold was taken in a stepwise 
manner from the 85th percentile within 
the contrast-enhancing component. After 
initial inspection, it was decided that if the 
resulting ADC-rCBV ROIs were too small 
for spectroscopic analysis, less than half 
the volume (1 cm3) of the spectroscopy 
10 3 10 3 15–20 mm; acquisition time, 
486 seconds).
Image Processing and ROI Selection
All images were coregistered to the 
T2-weighted images by using an affine 
transformation with the Functional MRI 
of the Brain (or FMRIB) Linear Image 
Registration Tool (or FLIRT) in FMRIB 
Software Library (FMRIB, Oxford, Eng-
land). T2-weighted images were used 
to guide spectroscopic data acquisition. 
Spectroscopy data were processed with 
the LCModel (Provencher, Oakville, On-
tario, Canada). All relevant spectra from 
chemical shift imaging voxels of interest 
were assessed for artifacts by using previ-
ously published criteria (36). The values 
of the Cramer-Rao lower bounds were 
used to evaluate the quality and reliability 
of chemical shift imaging data, and values 
with a standard deviation greater than 
20% were discarded. Dynamic suscepti-
bility contrast-enhanced data were pro-
cessed offline by using NordicICE (Nor-
dicNeuroLab, Bergen, Norway). Maps 
Figure 2
Figure 2: T1-weighted contrast-enhanced MR image set shows how chemical shift imaging voxels were 
included for analysis and where the ROI (magenta) was present inside the voxels along the x-, y-,  
and z-axes.
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a function of ROI volume and propor-
tional ROI volume (percentage of con-
ventional lesion, contrast-enhancing or 
nonenhancing). Cox regression account-
ed for confounders of GBM survival: 
age, contrast-enhancing volume, IDH-
1 mutation status, MGMT-methylation 
status, and extent of resection. To com-
pare relative accuracies for association 
with median OS and PFS, receiver oper-
ating characteristic curves were gener-
ated for ROI volumes. Their accuracies 
were compared with the area under the 
receiver operating characteristic curve.
Results
Interrater variability of the manu-
ally segmented regions showed good 
agreement, with a mean Dice similarity 
coefficient score of 0.88 6 0.04 (stan-
dard deviation). Complete resection 
of the contrast-enhancing region was 
achieved in 38 (81%) of 47 patients, 
while the remaining nine patients under-
went partial resection. Median OS was 
at a two-sided significance level of a = 
.05. Cho/NAA ratios were not normally 
distributed, and a log transformation 
was applied prior to analysis of variance, 
with posthoc analysis with Bonferroni 
correction used for multiple compari-
sons. Cho/NAA data were not normally 
distributed, and log transformation was 
applied prior to analysis of variance. Af-
ter Bonferroni correction for multiple 
comparisons, the adjusted significance 
level among the location groups was a 
= .008 (.05/6 = .008). All volume data 
were not normally distributed and were 
log transformed prior to statistical test-
ing. Differences in volume between the 
main ROIs and the test ROIs were ex-
plored by using the Student t test, as 
all test ROIs were significantly larger 
than their respective main ROIs. Corre-
lations between ROI volume and their 
corresponding conventional region vol-
ume were explored by using Pearson 
correlation. Volumes were dichotomized 
as high or low by using the median. Ka-
plan-Meier statistics analyzed survival as 
to the presence of that ROI and were not 
due to the surrounding non-ROI regions 
colocalizing the chemical shift imaging 
voxel. As the ADC-rCBV ROIs were char-
acterized by using Cho/NAA ratios, the 
control regions were based on chemical 
shift imaging voxels. Two sets of controls 
were identified by using chemical shift 
imaging voxels. These were (a) abnor-
mal control regions, which were voxels 
within contrast-enhancing and nonen-
hancing areas that did not meet the 
ADC-rCBV ROI criteria, and (b) contra-
lateral normal-appearing white matter. 
Regions for analysis included these two 
control regions: ADC-rCBV ROIs in con-
trast-enhancing regions and ADC-rCBV 
ROIs in nonenhancing regions (Fig 3). 
Lastly, the ADC-rCBV ROI volume 
and the conventional ROI volume were 
calculated by using Matlab software 
(Mathworks).
Statistical Analysis
Data were analyzed with IBM SPSS soft-
ware (version 22.0; IBM, Armonk, NY) 
Figure 3
Figure 3: T1-weighted contrast-enhanced MR image shows the four regions for metabolic assessment, with example spectra of NAA at 2.0 and Cho at 3.2. Exam-
ples include the ADC-rCBV ROI (magenta) in a chemical shift imaging voxel with a Cho/NAA ratio of 1.8 in the contrast-enhanced area (1) and 0.6 in the unenhanced 
area (2). Also shown are example spectra of an abnormal control region that does not meet the ROI criteria of low ADC with intersecting high rCBV (3) with a Cho/NAA 
ratio of 0.3 and normal-appearing white matter (4) with a Cho/NAA ratio of 0.2.
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a total of 41 voxels analyzed. Chemical 
shift imaging voxels colocalized with 
ADC-rCBV ROIs in nonenhancing re-
gions in 23 (71%) of 32 patients, with 
a total of 43 voxels analyzed. Chemi-
cal shift imaging voxels colocalized 
with ADC-rCBV ROIs in both contrast-
enhancing and nonenhancing regions 
in 13 (40%) of 32 patients. In the 32 
patients, a total of 38 eligible chemi-
cal shift imaging voxels were identified 
within the abnormal control regions, 
and 39 eligible chemical shift imaging 
voxels were identified in the contralat-
eral normal-appearing white matter.
Regions for Analysis
The Cho/NAA ratios of ADC-rCBV 
ROIs located in contrast-enhancing 
and nonenhancing regions were similar 
(95% confidence interval [CI]: 0.008, 
0.136; P = .017) (Table 1, Fig 4). Both 
were significantly greater than that in 
the abnormal control region (95% CI: 
0.086, 0.217; P , .001 for contrast-en-
hancing region) (95% CI: 0.015, 0.144; 
P = .008 for nonenhancing region). The 
Cho/NAA ratio of ADC-rCBV ROIs in 
contrast-enhancing and nonenhancing 
regions was significantly greater than 
that in normal-appearing white matter 
(95% CI: 0.122, 0.252; P , .001 for 
contrast-enhancing region) (95% CI: 
0.051, 0.179; P , .001 for nonenhanc-
ing region). No significant difference in 
Cho/NAA ratio was detected between 
the abnormal control region and nor-
mal-appearing white matter (95% CI: 
20.031, 0.102; P = .921).
ROIs. The ADC-rCBV ROIs were pre-
sent in 43 (92%) of 47 patients and 
were situated outside the chemical 
shift imaging grid in eight (18%) of 43 
patients. NAA values were unusable in 
three (6%) of 43 patients because the 
Cramer-Rao lower bounds standard 
deviation was greater than 20%. Thus, 
the sample size for metabolic assess-
ment was 32 patients. Chemical shift 
imaging voxels colocalized with ADC-
rCBV ROIs in contrast-enhancing re-
gions in 20 (62%) of 32 patients, with 
326 days (range, 27–1193 days). Me-
dian PFS was 224 days (range, 27–1130 
days).
Regions of Interest
The thresholds of the 85th percentile 
rCBV (rCBV = 4.4) and the 75th per-
centile rCBV (rCBV = 3.4) generated 
ADC-rCBV ROIs that were too small 
for metabolic analysis. Thus, the 65th 
percentile rCBV (rCBV = 2.7) and 
the 15th percentile ADC (normalized 
threshold, 1.2) were used to generate 
Figure 4
Figure 4: A, MR image shows boundaries of contrast enhancement (CE) (blue) and nonenhancement (NE) 
(yellow) used to categorize the ADC-rCBV ROI (magenta) Cho/NAA ratio according to location. B, Means plot 
shows results from the posthoc homogeneous subset tests, with Cho/NAA ratio from contrast-enhanced 
and unenhanced areas in a separate subset from Cho/NAA ratio from abnormal control tumor regions and 
normal-appearing white matter (NAWM). Lines extending from the bars show standard error of the mean. 
* = P < .01, ** = P < .001.
Table 1
Cho/NAA Ratios within the Four Locations
Region
No. of Voxels  
Tested
Difference
Descriptive ROI in NE Control NAWM
Mean 6 Standard  
Deviation 95% CI
Estimated  
Difference P Value
Estimated  
Difference P Value
Estimated  
Difference P Value
ROI in CE 41 0.291 6 0.153 0.243, 0.334 0.072 (0.024) .017 0.151 (0.025) ,.001* 0.187 (0.024) ,.001*
ROI in NE 43 0.220 6 0.137 0.178, 0.262 … … 0.079 (0.024) .008* 0.115 (0.024) ,.001*
Control 38 0.140 6 0.048 0.124, 0.156 … … … … 0.036 (0.025) .921
NAWM 39 0.104 6 0.039 0.092, 0.118 … … … … … …
Note.—Data in parentheses are the standard error. CE = contrast-enhancing area, NAWM = normal-appearing white matter, NE = nonenhancing area.
* Adjusted significance level a .05/6 = .0083.
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positively correlated with contrast-en-
hancing volume (r = 0.291, P = .014). 
ADC-rCBV ROI volume inside the non-
enhancing region positively correlated 
with nonenhancing volume (r = 0.350, 
P = .021). Total ADC-rCBV ROI volume 
and total lesion volume did not correlate 
(r = 0.291, P = .059). The differences 
between main ROIs and test ROIs are 
described in Table 3.
20.159, 0.010; P = .027, respectively) in 
nonenhancing regions were significantly 
larger in patients older than 60 years. 
In 30 (70%) of 43 patients, ADC-rCBV 
ROIs were larger in nonenhancing re-
gions than in contrast-enhancing regions 
(estimated difference, 0.510; standard 
error, 0.095; 95% CI: 20.704, 0.322; 
P , .001). The ADC-rCBV ROI volume 
inside the contrast-enhancing region 
As ADC-rCBV ROIs were absent or 
smaller than 1 cm3 in four (8%) of 47 
patients, volumetric analysis was per-
formed in 43 patients for raw and pro-
portional volumes (Table 2). Both ADC-
rCBV ROI volume (estimated difference, 
0.636; standard error, 0.242; 95% CI: 
21.139, 1.133; P = .016) and proportion 
of ADC-rCBV ROI (estimated difference, 
0.039; standard error, 0.049; 95% CI: 
Table 2
ROI Volumes and Relevant Patient Characteristics
Parameter
No. of  
Patients
Total ROI ROI in CE ROI in NE
Mean 6 SD P Value Mean 6 SD P Value Mean 6 SD P Value
Volume (cm3)
Total volume ... 46.50 6 67.70 ... 18.56 6 33.50 ... 26.86 6 36.11 ...
Age at diagnosis
 ,60 y 14 21.10 6 27.08 .053 12.13 6 21.62 .213 8.44 6 9.13 .016
 60 y 29 58.12 6 95.19 … 20.88 6 45.54 … 35.60 6 49.06 …
Sex
 Male 32 50.38 6 9260 .740 19.90 6 44.73 .635 29.09 6 47.71 .896
 Female 11 33.51 6 28.36 … 12.60 6 15.52 … 19.94 6 20.50 …
Extent of resection
 Complete 34 35.38 6 53.80 .107 14.35 6 27.12 .258 20.07 6 28.95 .062
 Partial 9 86.42 6 142.4 … 31.96 6 69.26 … 52.00 6 71.18 …
MGMT-methylation status*
 Methylated 16 61.99 6 110.3 .952 25.36 6 53.44 .404 34.81 6 57.05 .895
 Unmethylated 24 38.06 6 60.22 … 13.21 6 28.64 … 23.81 6 32.31 …
IDH-1 mutation status†
 Mutant 1 79.67 … 68.16 … 0.11 …
 Wild type 42 45.26 6 81.91 … 16.84 6 38.98 … 27.12 6 42.83 …
Volume Proportion (%)
Age at diagnosis
 ,60 y 14 3.86 6 7.53 .443 6.31 6 11.81 .875 1.97 6 2.86 .027
 60 y 29 5.12 6 6.95 … 5.73 6 7.80 … 5.64 6 7.48 …
Sex
 Male 32 5.16 6 7.91 .570 5.79 6 9.77 .595 4.90 6 7.34 .465
 Female 11 3.42 6 3.75 … 6.28 6 7.48 … 3.11 6 3.22 …
Extent of resection
 Complete 34 4.48 6 6.94 .710 5.82 6 9.46 .797 3.92 6 5.76 .478
 Partial 9 5.58 6 7.98 … 6.27 6 8.38 … 6.43 6 9.08 …
MGMT methylation status*
 Methylated 16 5.94 6 8.38 .418 7.32 6 10.70 .353 5.59 6 7.29 .434
 Unmethylated 24 3.92 6 6.27 … 4.61 6 7.43 … 3.96 6 6.39 …
IDH-1 mutation status†
 Mutant 1 27.12 … 39.52 … 9.77 …
 Wild type 42 4.18 6 6.23 … 5.12 6 7.59 … 4.32 6 6.57 …
Note.—CE = contrast-enhancing area, NE = nonenhancing area, SD = standard deviation.
* MGMT-methylation status was unavailable in three patients.
† Only one patient with IDH-1 mutation; mean 6 SD of original data.
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receiver operating characteristic curve, 
0.717; P = .034) (Fig 6).
Discussion
This study has shown that low-ADC 
ROIs with intersecting high rCBV depict 
1H MR spectroscopy features that sug-
gest tumor presence in both contrast-
enhancing and nonenhancing regions, 
and an increased proportion of these 
ROIs within the nonenhancing region 
is associated with poor patient survival. 
The nonenhancing component is typi-
cally left behind after surgical resection 
of the contrast-enhancing component; 
therefore, studies of this nature can offer 
insight into the subregions that may be 
responsible for local GBM recurrence.
Although previous studies have sug-
gested use of an rCBV greater than 3 to 
identify tumor in the contrast-enhancing 
area (9,16), a reduced threshold was 
considered reasonable for assessment 
outside the contrast-enhancing area, 
where median rCBV values typically 
significantly contributed to the multivari-
ate model of OS. The proportion of non-
enhancing regions with ADC-rCBV ROI 
(hazard ratio, 1.454; P = .017), extent of 
resection (hazard ratio, 0.013; P = .031), 
and IDH-1 mutation status (hazard ratio, 
0.000; P = .011) significantly contributed 
to the multivariate model of PFS.
Cox regression results for test ROIs 
and main ROIs were similar. The propor-
tion of nonenhancing regions with ADC-
rCBV ROI (hazard ratio, 1.179; P = .014), 
extent of resection (hazard ratio, 0.113; P 
= .018), and IDH-1 mutation status (haz-
ard ratio, 0.001; P = .003) significantly 
contributed to the multivariate model of 
OS. In the analysis of PFS, the proportion 
of nonenhancing regions with ADC-rCBV 
ROI (hazard ratio, 1.149; P = .050), ex-
tent of resection (hazard ratio, 0.073; P = 
.011), and IDH-1 mutation status (hazard 
ratio, 0.004; P = .007) were significant 
contributors. The proportion of ADC-
rCBV ROI in nonenhancing regions was 
the only variable with significant associ-
ation with median OS (area under the 
Survival Statistics
After univariate analysis, the volume of 
ADC-rCBV ROI in contrast-enhancing 
regions was associated with poor OS 
(log-rank P = .040) (Table 4). The pro-
portion of contrast-enhancing and non-
enhancing regions with ADC-rCBV ROI 
was associated with poor OS (log-rank 
P = .010), and the proportion of non-
enhancing regions with ADC-rCBV ROI 
was associated with poor OS (log-rank P 
= .017) (Fig 5). Assessment of age, con-
trast-enhancing volume, IDH-1 mutation, 
MGMT-methylation status, and extent of 
resection independently showed that only 
extent of resection had a significant as-
sociation with both OS (P = .022) and 
PFS (P = .041). After we accounted for 
all the previously mentioned confounders 
and censored four cases with no re-
corded date of progression or death, the 
proportion of nonenhancing regions with 
ADC-rCBV ROI (hazard ratio, 1.132; P 
= .026), extent of resection (hazard ra-
tio, 0.090; P = .011), and IDH-1 muta-
tion status (hazard ratio, 0.010; P = .008) 
Table 3
Volume Differences between Main ROIs and Test ROIs
ROI
Original and Log-transformed Data* Difference (Log-transformed data)
Normalized Global  
Threshold (Main ROI)
Individualized Percentile  
Threshold (Test ROI) Estimated Difference 95% CI t Statistic P Value
Total ROI volume
 Original volume/value 46.503 6 67.709 78.367 6 50.594 … … … …
 Log-transformed value 3.140 6 0.850 3.777 6 0.361 20.641 (0.128) 20.899, 20.382 24.998 ,.001
ROI volume in CE
 Original volume/value 18.563 6 33.504 19.546 6 18.623 … … … …
 Log-transformed value 2.440 6 1.054 3.061 6 0.504 20.626 (0.146) 20.921, 20.331 24.227 ,.001
ROI volume in NE
 Original volume/value 26.864 6 36.114 57.142 6 44.648 … … … …
 Log-transformed value 2.948 6 0.801 3.556 6 0.530 20.608 (0.125) 20.861, 20.355 24.855 ,.001
Proportion total ROI CE + NE
 Original/proportion value 5.105 6 7.055 6.392 6 1.953 … … … …
 Log-transformed value 0.521 6 0.431 0.854 6 0.115 20.333 (0.070) 20.474, 20.193 24.788 ,.001
Proportion ROI CE
 Original/proportion value 6.574 6 8.860 7.618 6 5.879 … … … …
 Log-transformed value 0.553 6 0.482 0.839 6 0.305 20.286 (0.076) 20.439, 20.133 23.774 ,.001
Proportion ROI NE
 Original/proportion value 5.030 6 7.213 7.550 6 5.711 … … … …
 Log-transformed value 0.519 6 0.414 0.862 6 0.247 20.343 (0.075) 20.494, 20.191 24.568 ,.001
Note.—Data in parentheses are the standard error. Main ROI is the normalized threshold using an ADC cutoff of 1.2 and an rCBV cutoff of 2.7. The test ROI is the individualized thresholds based on the 
15th percentile ADC and the 65th percentile rCBV, per patient. CE = contrast-enhancing area, NE = nonenhancing area.
* Data are mean 6 standard deviation.
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are lower (9,40). Additionally, a previ-
ous study (40) has suggested use of a 
threshold identical to that reported here 
for biopsy sampling within the contrast-
enhancing area in the region with the 
highest rCBV, from 2.7 (9). A low-ADC 
threshold was used because of its in-
verse association with tumor cellularity, 
proliferation, and architectural disrup-
tion in nonenhancing areas (9,10,13). As 
the ADC threshold was generated from 
voxels in contrast-enhancing areas and 
from those in nonenhancing areas, its 
normalized value was not expected to be 
less than 1.00. However, this finding is 
in accordance with findings of a previous 
study that inversely correlated ADC with 
cellularity with a pooled mean ADC min-
imum of 1.2 (r = 0.77, P = .007) (13). 
Previous work using Cho and NAA has 
yielded findings in accordance with those 
Table 4
Survival Statistics
Variable and Test
PFS OS
Hazard Ratio 95% CI AUC P Value Hazard Ratio 95% CI AUC P Value
Total ROI volume
 Log-rank test … … … .076 … … … .270
 Cox regression 1.000 1.000, 1.000 … .254 1.000 1.000, 1.000 … .224
 ROC … 0.384, 0.816 0.600 .351 … 0.433, 0.824 0.629 .207
ROI volume in CE
  Log-rank test … … … .076 … … … .040*
 Cox regression 1.000 1.000, 1.000 … .483 1.000 1.000, 1.000 … .327
 ROC … 0.356, 0.786 0.571 .507 … 0.398, 0.793 0.596 .349
ROI volume in NE
  Log-rank test … … … .230 … … … .509
 Cox regression 1.000 1.000, 1.000 … .125 1.000 1.000, 1.000 … .165
 ROC … 0.351, 0.787 0.569 .520 … 0.437, 0.827 0.632 .195
Proportion total ROI (in CE and NE)
 Log-rank test … … … .076 … … … .010*
 Cox regression 1.037 0.971, 1.108 … .281 1.064 0.976, 1.159 … .160
 ROC … 0.419, 0.843 0.631 .221 … 0.437, 0.827 0.632 .195
Proportion ROI in CE
 Log-rank test … … … .614 … … … .637
 Cox regression 1.046 0.977, 1.120 … .196 1.039 0.974, 1.109 … .248
 ROC … 0.382, 0.809 0.596 .373 … 0.347, 0.749 0.548 .640
Proportion ROI in NE
 Log-rank test … … … .067 … … … .017*
 Cox regression 1.454 1.000, 1.000 … .017 1.132 1.015, 1.263 … .026*
 ROC … 0.485, 0.901 0.693 .071 … 0.541, 0.893 0.717 .034*
Note.—Cox-regression model accounting for patient age, enhancing tumor volume, MGMT-methylation status, IDH-1 mutation status, and extent of resection. AUC = area under the receiver operating 
characteristic curve, CE = contrast-enhancing area, NE = nonenhancing, and ROC = receiver operating characteristic curve.
* P value indicates a significant difference. 
Figure 5
Figure 5: Kaplan-Meier plots show larger proportions of ADC-rCBV ROI in nonenhancing (NE) areas, A, 
were associated with worse OS (P = .017) and, B, trended with poor PFS (P = .067). Volumes were catego-
rized as high or low by using relevant median values.
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reported here, where an elevated Cho/
NAA ratio or index was identified out-
side the area of contrast enhancement 
(16), and has even led to identification 
of tumor extent outside the area of con-
trast enhancement (41). With regard to 
the nonenhancing region, Jain et al (27) 
previously reported elevated rCBV in the 
nonenhancing region to be associated 
with poor survival. However, they iden-
tified nonenhancement as a 1-cm fluid-
attenuated inversion recovery border 
around the region of contrast enhance-
ment; whereas in our study, we identified 
the nonenhancing region as the entire 
area of fluid-attenuated inversion recov-
ery hyperintensity surrounding the con-
trast-enhancing region. Previous work 
that used low ADC, high rCBV, and Cho 
and NAA for survival analyses did not an-
alyze regional low ADC that intersected 
with high rCBV, and all parameters were 
considered individual variables (16).
Figure 6
Figure 6: Receiver operating characteristic curves compare relative accuracies in association between ADC-rCBV ROI volumes and propor-
tions with median OS. The only measure with significant association was the proportion of ADC-rCBV ROI in the nonenhancing area (NE) (area 
under the receiver operating characteristic curve [AUC], 0.717; P = .034). CE = contrast-enhancing area.
Our study had limitations. The im-
aging thresholds reported in this article 
are derived from our own population 
and were not independently tested. 
Since they are from one center and are 
from retrospective data analysis, addi-
tional studies will be needed for confir-
mation. The 1H MR spectroscopy voxels 
were large in comparison with the ADC 
and rCBV voxels. Histologic data for this 
cohort were not obtained, as the brain 
shift during surgery did not allow for ac-
curate image-guided data acquisition. Fi-
nally, our study protocol did not include 
quantitative T1 or T2 parameters.
In summary, as the nonenhancing 
component is typically left behind af-
ter surgery, studies of this nature may 
be useful in identifying subregions that 
would be better suited for targeted 
boost radiation therapy volumes or po-
tential sites of extended surgical resec-
tion of GBM.
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